Title |
Prospective Validation Obtained in a Similar Group of Patients and with Similar High Throughput Biological Tests Failed to Confirm Signatures for Prediction of Response to Chemotherapy and Survival in Advanced NSCLC: A Prospective Study from the European Lung Cancer Working Party
|
---|---|
Published in |
Frontiers in oncology, January 2015
|
DOI | 10.3389/fonc.2014.00386 |
Pubmed ID | |
Authors |
Thierry Berghmans, Lieveke Ameye, Jean-Jacques Lafitte, Benoît Colinet, Alexis Cortot, Ingrid CsToth, Stéphane Holbrechts, Jacques Lecomte, Céline Mascaux, Anne-Pascale Meert, Marianne Paesmans, Michel Richez, Arnaud Scherpereel, Christian Tulippe, Luc Willems, Tiffany Dernies, Nathalie Leclercq, Jean-Paul Sculier, for the European Lung Cancer Working Party |
Abstract |
Cisplatin doublets are standard 1st line treatment for advanced non-small cell lung cancer (NSCLC), without accurate predictor for response and survival, but important toxicity. Our aims were to identify predictive (for response) and prognostic (for survival) biological signatures in patients with NSCLC using messenger RNAs (mRNA) and miRNA expression. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
France | 1 | 33% |
Switzerland | 1 | 33% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 19 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 4 | 21% |
Student > Ph. D. Student | 4 | 21% |
Lecturer | 2 | 11% |
Student > Bachelor | 2 | 11% |
Student > Doctoral Student | 1 | 5% |
Other | 2 | 11% |
Unknown | 4 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 5 | 26% |
Nursing and Health Professions | 3 | 16% |
Biochemistry, Genetics and Molecular Biology | 2 | 11% |
Engineering | 2 | 11% |
Computer Science | 1 | 5% |
Other | 2 | 11% |
Unknown | 4 | 21% |